CytomX Therapeutics (CTMX) Tops Q1 EPS by 2c

CytomX Therapeutics (NASDAQ: CTMX) reported Q1 EPS of ($0.10), $0.02 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $10.26 million versus the consensus estimate of $4.64 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Wealthfront launches custodial account with tax-gain harvesting